Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295165 · ClinicalTrials.gov registry record · Phase 3
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 33
- Enrollment target
NCT00295165 is a Phase 3 study that was terminated before completion, run by Genzyme, a Sanofi Company. The registered enrollment target is 33 participants.
The verdict
NCT00295165, a Phase 3 study, was terminated before completion, sponsored by Genzyme, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease.
Interventions
- DRUG Placebo
- DRUG Sargramostim (Leukine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00295165
The ClinicalTrials.gov registry entry for NCT00295165 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00295165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00295165 about?
NCT00295165 is a clinical study titled "Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease". The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease.
What is the current status of trial NCT00295165?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 33 participants. The study started on 2006-01. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00295165?
The interventions under investigation include: Placebo (DRUG), Sargramostim (Leukine) (DRUG).
Who is sponsoring clinical trial NCT00295165?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.